OCGN — Ocugen, Inc. stock price, charts and financials

QT46Ocugen, Inc.

Ocugen, Inc. (NASDAQ: OCGN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1.31
+0.03+2.34%
OverviewShort InterestFilings
OCGNQT46Ocugen, Inc.·NASDAQ
1.31+2.34%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.52%$15.45MESO+4.64%$16.68ZBIO-1.48%$31.95GHRS-2.44%$29.53TSHA-2.90%$6.37STOK-1.47%$32.23ABCL+34.78%$9.34VRDN-2.25%$23.06
Snapshot
Index-P/E-EPS (ttm)-0.22Insider Own8.31%Shs Outstand339.11MPerf Week4.07%
Market Cap434.06MForward P/E-EPS next Y-0.24Insider Trans0.07%Shs Float315.73MPerf Month-12.93%
Enterprise Value420.27MPEG0.24EPS next Q-Inst Own-Short Float31.86%Perf Quarter-11.11%
Income-81.91MP/S94.77EPS this Y-1.51%Inst Trans-Short Ratio12.90Perf Half Y-3.76%
Sales4.58MP/B-EPS next Y-8.58%ROA-65.87%Short Interest100.59MPerf YTD-5.19%
Book/sh-P/C-EPS next 5Y-ROE1688.22%52W High2.79 -53.11%Perf Year33.57%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-92.68%52W Low0.97 35.45%Perf 3Y123.00%
Dividend Est.-EV/EBITDA-Sales past 3/5Y25.99% -Gross Margin-Volatility5.69% 5.34%Perf 5Y-80.92%
Dividend TTM-EV/Sales91.76EPS Y/Y TTM-10.00%Oper. Margin-1504.43%ATR (14)0.08Perf 10Y-98.93%
Dividend Ex-Date-Quick Ratio0.80Sales Y/Y TTM25.00%Profit Margin-1786.27%RSI (14)46.71Recom2.17
Dividend Gr. 3/5Y-Current Ratio0.80EPS Q/Q-20.00%SMA20-1.31%Beta2.14Target Price5.00
Payout0.00%Debt/Eq-Sales Q/Q100.00%SMA50-4.38%Rel Volume0.66Prev Close1.28
Employees116LT Debt/Eq-2.58EarningsNov 04SMA200-15.61%Avg Volume6.84MPrice1.31
IPO DateDec 03, 2014Option/ShortNo / YesEPS/Sales Surpr.2.78% 266.89%Net Debt/EBITDA0.20Volume4,530,398Change2.34%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-01-23UpgradeChardan CapitalNeutral → Buy
Aug-23-22InitiatedMizuhoBuy$5.00
Aug-15-22ReiteratedHC Wainwright & Co.Buy
Jun-18-22ReiteratedCantor FitzgeraldNeutral$4.50
May-08-22ReiteratedChardan CapitalNeutral$3.50
Apr-25-22ReiteratedRoth CapitalNeutral
Jun-11-21DowngradeRoth CapitalBuy → Neutral
May-07-21DowngradeCantor FitzgeraldOverweight → Neutral
Feb-09-21DowngradeChardan CapitalBuy → Neutral
Feb-04-21UpgradeHC Wainwright & Co.Neutral → Buy
Latest News
Aug-07-26
Aug-07-2602:21PM
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Fallszacks.com
02:05AM
Ocugen Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2605:04PM
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:51AM
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimateszacks.com
07:02AM
Ocugen Provides Business Update with Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-31-26
Jul-31-2607:02AM
Ocugen to Participate in Upcoming August Investor Conferencesglobenewswire.com
Jul-29-26
Jul-29-2607:13AM
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular DegenerationBenzinga
07:01AM
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degenerationglobenewswire.com
Jul-28-26
Jul-28-2604:01PM
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-13-26
Jul-13-2607:16AM
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North AfricaBenzinga
07:02AM
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africaglobenewswire.com
Jul-10-26
Jul-10-2608:02PM
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advancesmarketbeat.com
Jul-01-26
Jul-01-2607:00AM
Ocugen to Participate in Upcoming July Industry Conferencesglobenewswire.com
Jun-25-26
Jun-25-2612:35AM
Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To WorkSeekingAlpha
Company

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue544——————
Cost of Goods Sold Incl. D&A022——————
Gross Profit522——————
Selling, General and Administrative Excl. Other272827——————
Research and Development374032——————
Other Operating Expense1-3-2——————
Operating Income-61-63-55——————
Interest Expense350——————
Unusual Expense
—————————
Non-Operating Income (Expense)-101——————
Net Income Before Taxes-64-68-54——————
Income Taxes
000——————
Consolidated Net Income-64-68-54——————
Net Income From Continuing Operations-64-68-54——————
Net Income-64-68-54——————
EPS (Recurring)-0.22-0.23-0.20——————
EPS (Basic, Before Extraordinaries)-0.22-0.23-0.20——————
EPS (Diluted)-0.22-0.23-0.20——————
EBITDA-58-60-52——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio79.65101.2554.54——————
Gross Margin100.0050.0050.00——————
Operating Margin-1,220.00-1,575.00-1,375.00——————
Net Margin-1,280.00-1,700.00-1,350.00——————
Shares Outstanding304300271——————
Market Capitalization398405218——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$2.73$2.19$1.66$1.12$0.59● Close Price0.00K6.46K12.91K19.37K25.83KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Johnson-Greene Treerita EssalimaChief Financial OfficerJun 15 '26Buy1.2321,00025,830521,000Jun 17
Zhang JungeDirectorApr 01 '26Option Exercise0.79194,134154,3031,359,316Apr 02
Fernandes PrabhavathiDirectorNov 26 '24Buy0.9110,0009,09510,000Dec 02
Castillo KirstenDirectorNov 22 '24Buy0.9125,00022,84875,000Nov 26
Zhang JungeDirectorJun 14 '23Buy0.50200,27899,9991,077,182Jun 16
Musunuri ShankarChief Executive OfficerFeb 16 '23Option Exercise0.33100,00033,0002,290,073Feb 17
Musunuri ShankarChief Executive OfficerFeb 16 '23Sale1.08100,000108,0002,190,073Feb 17
Musunuri ShankarChief Executive OfficerJan 17 '23Option Exercise0.51100,00051,0002,327,950Jan 19
Musunuri ShankarChief Executive OfficerJan 17 '23Sale1.28100,000128,0002,227,950Jan 19
Musunuri ShankarChief Executive OfficerDec 16 '22Option Exercise0.5195,80948,863848,349Dec 20
Musunuri ShankarChief Executive OfficerDec 16 '22Sale1.4395,809137,007752,540Dec 20
Musunuri ShankarChief Executive OfficerOct 14 '22Option Exercise0.51100,00051,000852,540Oct 14
Musunuri ShankarChief Executive OfficerOct 14 '22Sale1.66100,000166,000752,540Oct 14
Kumar RameshDirectorOct 06 '22Option Exercise0.514,5002,2954,500Oct 07
Kumar RameshDirectorOct 06 '22Sale1.834,5008,2350Oct 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.